This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2019.
Company Filing History:
1 out of 834,411 Years Active: 2019
Title: Chiara De Luca: Innovator in Cancer Detection
Introduction
Chiara De Luca is a prominent inventor based in Rome, Italy. She has made significant contributions to the field of cancer research, particularly in the early detection of transforming cells in pre-neoplastic tissues. Her innovative work has the potential to improve patient outcomes in cancer treatment.
Latest Patents
Chiara De Luca holds 1 patent for her invention titled "Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject." This patent describes a monoclonal antibody that specifically binds to the human Long Interspersed Element-1 ORF2 encoded protein (L1-ORF2p). The invention includes methods for early detection of cell transformation in pre-neoplastic tissues, which can indicate the presence of cancerous changes. Additionally, it provides a method for monitoring the progression of colon adenoma by detecting increased expression of L1-ORF2p.
Career Highlights
Throughout her career, Chiara has focused on advancing cancer detection methodologies. Her research has been instrumental in developing tools that can predict patient responses to NNRTI treatments, thereby personalizing cancer therapy.
Collaborations
Chiara has collaborated with notable colleagues, including Paola Sinibaldi-Vallebona and Fiorella Guadagni. These partnerships have enhanced her research and contributed to the advancement of cancer detection technologies.
Conclusion
Chiara De Luca is a trailblazer in the field of cancer research, with her innovative patent paving the way for improved detection methods. Her work exemplifies the impact of scientific innovation on healthcare and patient treatment strategies.